JM

Cascade BioSciences Inc.

TSX: CSBX

Mid-cap oncology developer. Lead candidate CSB-204 in Phase II. Disclosure quality has deteriorated across the last two reporting cycles.

OverviewFlagsFilingsContradictionsRisksNetworkEnforcementInsider trades

Governance

Officers

  • Dr. Eleanor WhitcombeCEO
  • Marcus LeungCFO
  • Priya Naidu, Ph.D.Chief Scientific Officer

Board

  • Dr. Eleanor Whitcombe
  • Benoît Laurier
  • Aisha McKendrick
  • David Hollander
  • Natalie Ostrowski
  • Isabela Mendez

Company facts

HQ
Toronto, ON
Regulator
OSC
Market cap
$612.8M
Incorporated
Jul 19, 2011

Corporate timeline

  1. Jul 19, 2011
    Incorporated under the Canada Business Corporations Act
    Incorporation

    Federal incorporation; Toronto head office.

  2. Nov 09, 2014
    Listed on the Toronto Stock Exchange
    Listing

    Graduated from TSXV; offering of 8.0M units at $4.50.

  3. Jan 22, 2018
    Eleanor Whitcombe appointed CEO
    Director Change

    Founder transition; clinical-stage strategy pivot.

  4. Feb 14, 2023
    Out-licensed early-stage cardio assets to Merevix
    Restructuring

    Upfront $6.0M plus milestones; royalties on net sales.

Auditor history

2
Konig & Hartwell
Nov 09, 2014 → Aug 12, 2021

Tender process.

1
Ashford Whitman LLP
Aug 12, 2021 → Present

Current auditor.